Hyperkalemia Drugs Market by Type and Geography - Forecast and Analysis 2022-2026

The hyperkalemia drugs market share is expected to increase by USD 803.17 million from 2021 to 2026, and the market's growth momentum will accelerate at a CAGR of 18.65%.

This hyperkalemia drugs market research report provides valuable insights on the post COVID-19 impact on the market, which will help companies evaluate their business approaches. Furthermore, this report extensively covers hyperkalemia drugs market segmentations by type (chronic hyperkalemia and acute hyperkalemia) and geography (North America, Europe, Asia, and Rest of World (ROW)). The hyperkalemia drugs market report also offers information on several market vendors, including AdvaCare International, Ardelyx Inc., AstraZeneca Plc, CytoSorbents Corp., KVK Tech Inc., Sanofi SA, Steadfast MediShield Pvt. Ltd., and Vifor Pharma Management Ltd. among others.

What will the Hyperkalemia Drugs Market Size be During the Forecast Period?

Download the Free Report Sample to Unlock the Hyperkalemia Drugs Market Size for the Forecast Period and Other Important Statistics

 

Hyperkalemia Drugs Market: Key Drivers, Trends, and Challenges

The growing cases of chronic diseases is notably driving the hyperkalemia drugs market growth, although factors such as poor diagnosis may impede the market growth. Our research analysts have studied the historical data and deduced the key market drivers and the COVID-19 pandemic impact on the hyperkalemia drugs industry. The holistic analysis of the drivers will help in deducing end goals and refining marketing strategies to gain a competitive edge.

Key Hyperkalemia Drugs Market Driver

The growing cases of chronic diseases is one of the key drivers supporting the hyperkalemia drugs market growth. Chronic kidney diseases increase the risk of patients developing hyperkalemia significantly, as the kidneys lose the ability to excrete potassium through urine up to 10%. The ability of kidneys to excrete potassium decreases with time, which increases the risk of hyperkalemia becoming acute. The market has witnessed an increase in the prevalence of chronic kidney diseases due to factors such as age, diabetes, and hypertension. According to the Centers for Disease Control and Prevention (CDC), in 2021, more than one in seven, that is, 15% of adults in the US or 37 million people, are estimated to have chronic kidney disease. The condition is more common in people aged 65 years or older than in people aged 45-64 years or 18-44 years. Such increasing chronic diseases will drive market growth during the forecast period.

Key Hyperkalemia Drugs Market Trend

Patient assistance programs is one of the key hyperkalemia drugs market trends that is contributing to the market growth. For instance, the Patient Access Network Foundation, an organization that helps the underinsured people with life-threatening diseases, chronic diseases, and rare diseases to get the medications and treatments at a lower cost, is helping the patients undergoing treatment for hyperkalemia. Under the patient assistance program, the organization provides reimbursements up to $1,600 per year. This program covers the reimbursement or assistance for Kayexalate, Kionex, Lokelma, and Veltassa. Due to the variety of drugs being covered by the organization under the assistance program, a large part of patients, who are currently not undergoing treatment, is expected to benefit from the treatment, which is expected to contribute to the growth of the market during the forecast period.

Key Hyperkalemia Drugs Market Challenge

Poor diagnosis is one of the factors hindering the hyperkalemia drugs market growth. Sometimes, blood tests are misdiagnosed, as the high potassium levels in the blood could be due to pseudo hyperkalemia, which is a temporary increase in potassium levels caused due to electrolyte imbalance and is usually non-life-threatening. The use of drugs in cases of pseudo hyperkalemia could result in adverse side effects, which could lead to less efficacious treatment. However, the lack of advanced diagnostic methods for hyperkalemia and the asymptomatic nature of the disease is resulting in a large part of the patient population remaining undiagnosed. Hence, the poor diagnosis of the disease is expected to hinder the growth of the market during the forecast period.

This hyperkalemia drugs market analysis report also provides detailed information on other upcoming trends and challenges that will have a far-reaching effect on the market growth. The actionable insights on the trends and challenges will help companies evaluate and develop growth strategies for 2022-2026.

Parent Market Analysis

Technavio categorizes the hyperkalemia drugs market as a part of the global pharmaceutical market. Our research report has extensively covered external factors influencing the parent market growth potential in the coming years, which will determine the levels of growth of the hyperkalemia drugs market during the forecast period.

Who are the Major Hyperkalemia Drugs Market Vendors?

The report analyzes the market's competitive landscape and offers information on several market vendors, including:

 

• AdvaCare International
• Ardelyx Inc.
• AstraZeneca Plc
• CytoSorbents Corp.
• KVK Tech Inc.
• Sanofi SA
• Steadfast MediShield Pvt. Ltd.
• Vifor Pharma Management Ltd.

 

This statistical study of the hyperkalemia drugs market encompasses successful business strategies deployed by the key vendors. The hyperkalemia drugs market is concentrated and the vendors are deploying organic and inorganic growth strategies to compete in the market.

Product Insights and News

• Advacarepharma.com - The company offers hyperkalemia drug as relief in antagonizing the cardiac toxicity provided the patient is not receiving digitalis therapy, under the brand name CalcoCare.
• Ardelyx.com - The company offers hyperkalemia drug that targets potassium secretion through the lumen of the gut, which is still in development under RDX013.
• Astrazeneca.com - The company offers hyperkalemia drug that provides rapid and sustained potassium control for patients, under the brand name Lokelma.

To make the most of the opportunities and recover from post COVID-19 impact, market vendors should focus more on the growth prospects in the fast-growing segments, while maintaining their positions in the slow-growing segments.

The hyperkalemia drugs market forecast report offers in-depth insights into key vendor profiles. The profiles include information on the production, sustainability, and prospects of the leading companies.

Hyperkalemia Drugs Market Value Chain Analysis

Our report provides extensive information on the value chain analysis for the hyperkalemia drugs market, which vendors can leverage to gain a competitive advantage during the forecast period. The end-to-end understanding of the value chain is essential in profit margin optimization and evaluation of business strategies. The data available in our value chain analysis segment can help vendors drive costs and enhance customer services during the forecast period.

Which are the Key Regions for Hyperkalemia Drugs Market?

For more insights on the market share of various regions Request for a FREE sample now!

38% of the market's growth will originate from North America during the forecast period. US and Canada are the key markets for the hyperkalemia drugs market in North America. Market growth in this region will be faster than the growth of the market in ROW.

The increasing prevalence of chronic kidney diseases and heart failure caused by the growing sedentary lifestyle will facilitate the hyperkalemia drugs market growth in North America over the forecast period. This market research report entails detailed information on the competitive intelligence, marketing gaps, and regional opportunities in store for vendors, which will assist in creating efficient business plans.

COVID Impact and Recovery Analysis

In 2020, the COVID-19 pandemic had a negative impact on the regional hyperkalemia drugs market. However, in H2 2020, due to the introduction of vaccines and a reduction in the number of COVID-19 cases in the region, hospitals and other healthcare facilities resumed elective procedures. Thus, the regional market is expected to witness growth during the forecast period.

What are the Revenue-generating Type Segments in the Hyperkalemia Drugs Market?

To gain further insights on the market contribution of various segments Request for a FREE sample

The hyperkalemia drugs market share growth by the chronic hyperkalemia segment will be significant during the forecast period. The chronic hyperkalemia segment holds the major share of the global hyperkalemia drugs market, primarily due to the strong presence of the indication. Factors such as the increasing prevalence and recurring nature of chronic hyperkalemia are also contributing to the growth of the segment. As most cases of hyperkalemia are mild, the disease is largely non-life-threatening. Owing to these factors, the market is expected to witness an accelerating growth momentum, with the highest year-over-year growth coming in the final year of the forecast period.

This report provides an accurate prediction of the contribution of all the segments to the growth of the hyperkalemia drugs market size and actionable market insights on post COVID-19 impact on each segment.

 

Hyperkalemia Drugs Market Scope
Report Coverage	Details
Page number	120
Base year	2021
Forecast period	2022-2026
Growth momentum & CAGR	Accelerate at a CAGR of 18.65%
Market growth 2022-2026	$ 803.17 million
Market structure	Concentrated
YoY growth (%)	18.08
Regional analysis	North America, Europe, Asia, and Rest of World (ROW)
Performing market contribution	North America at 38%
Key consumer countries	US, Canada, Germany, France, and UK
Competitive landscape	Leading companies, Competitive strategies, Consumer engagement scope
Key companies profiled	AdvaCare International, Ardelyx Inc., AstraZeneca Plc, CytoSorbents Corp., KVK Tech Inc., Sanofi SA, Steadfast MediShield Pvt. Ltd., and Vifor Pharma Management Ltd.
Market dynamics	Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID 19 impact and recovery analysis and future consumer dynamics, Market condition analysis for forecast period
Customization purview	If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized.

Request for a FREE sample

What are the Key Data Covered in this Hyperkalemia Drugs Market Report?

• CAGR of the market during the forecast period 2022-2026
• Detailed information on factors that will drive hyperkalemia drugs market growth during the next five years
• Precise estimation of the hyperkalemia drugs market size and its contribution to the parent market
• Accurate predictions on upcoming trends and changes in consumer behavior
• The growth of the hyperkalemia drugs industry across North America, Europe, Asia, and Rest of World (ROW)
• A thorough analysis of the market's competitive landscape and detailed information on vendors
• Comprehensive details of factors that will challenge the growth of hyperkalemia drugs market vendors

We can help! Our analysts can customize this report to meet your requirements. Get in touch